Jonas Sørensen1, Per Sjøgren2,3, Stine Novrup Clemmensen4, Tanja Vibeke Sørensen5, Katja Heinecke5, Geana Paula Kurita2,3,6. 1. Section of Palliative Medicine, Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. jonas.soerensen@regionh.dk. 2. Palliative Research Group, Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 3. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 4. Department of Hematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 5. Section of Palliative Medicine, Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 6. Multidisciplinary Pain Centre, Department of Neuroanaesthesiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Abstract
CONTEXT: In 2011, a multidisciplinary palliative team (MPT) was established at Rigshospitalet (DK) and a cross-sectional study in inpatients was carried out at the Departments of Oncology and Hematology. High symptom burden, high prevalence of pain (64%), and insufficient analgesic treatment were demonstrated. In 2019, a similar study was carried out. OBJECTIVES: This study compares prevalence of symptoms including pain and analyzes analgesic treatment of adult in-patients in a comprehensive cancer center. METHODS: Two cross-sectional studies (May-Jun 2011; Feb-Sep 2019). INCLUSION CRITERIA: malignant diseases, age ≥ 18 y, able to understand Danish. EORTC QLQ-C30 and Brief Pain Inventory (BPI) were applied. RESULTS: A total of 134 and 183 inpatients were included in 2011 and 2019, respectively. Differences in the two populations were seen; in 2019 more patients had advanced disease (P = 0.0096), lower performance status (P = 0.0028), and a palliative treatment plan (P = 0.0034). The prevalence of impairments and symptoms was high and similar in the 2 years with exception of severe pain (P = 0.0143) and neuropathic pain (P < 0.0001) which increased in 2019. Moreover, pain relief significantly improved, and significantly fewer patients with pain were left untreated. Significant increase in opioid and adjuvant analgesic prescription in 2019. CONCLUSION: An overall unchanged high symptom burden was observed. However, improvement of pain management was observed in 2019. The establishment of a MPT may possibly have contributed to improved pain management.
CONTEXT: In 2011, a multidisciplinary palliative team (MPT) was established at Rigshospitalet (DK) and a cross-sectional study in inpatients was carried out at the Departments of Oncology and Hematology. High symptom burden, high prevalence of pain (64%), and insufficient analgesic treatment were demonstrated. In 2019, a similar study was carried out. OBJECTIVES: This study compares prevalence of symptoms including pain and analyzes analgesic treatment of adult in-patients in a comprehensive cancer center. METHODS: Two cross-sectional studies (May-Jun 2011; Feb-Sep 2019). INCLUSION CRITERIA: malignant diseases, age ≥ 18 y, able to understand Danish. EORTC QLQ-C30 and Brief Pain Inventory (BPI) were applied. RESULTS: A total of 134 and 183 inpatients were included in 2011 and 2019, respectively. Differences in the two populations were seen; in 2019 more patients had advanced disease (P = 0.0096), lower performance status (P = 0.0028), and a palliative treatment plan (P = 0.0034). The prevalence of impairments and symptoms was high and similar in the 2 years with exception of severe pain (P = 0.0143) and neuropathic pain (P < 0.0001) which increased in 2019. Moreover, pain relief significantly improved, and significantly fewer patients with pain were left untreated. Significant increase in opioid and adjuvant analgesic prescription in 2019. CONCLUSION: An overall unchanged high symptom burden was observed. However, improvement of pain management was observed in 2019. The establishment of a MPT may possibly have contributed to improved pain management.
Authors: Annette S Strömgren; Dorthe Goldschmidt; Mogens Groenvold; Morten Aa Petersen; Pernille T Jensen; Lise Pedersen; Linda Hoermann; Carsten Helleberg; Per Sjogren Journal: Cancer Date: 2002-01-15 Impact factor: 6.860
Authors: Areej El-Jawahri; Thomas LeBlanc; Harry VanDusen; Lara Traeger; Joseph A Greer; William F Pirl; Vicki A Jackson; Jason Telles; Alison Rhodes; Thomas R Spitzer; Steven McAfee; Yi-Bin A Chen; Stephanie S Lee; Jennifer S Temel Journal: JAMA Date: 2016-11-22 Impact factor: 56.272
Authors: Morten Thronæs; Sunil X Raj; Cinzia Brunelli; Sigrun Saur Almberg; Ola Magne Vagnildhaug; Susanna Bruheim; Birgit Helgheim; Stein Kaasa; Anne Kari Knudsen Journal: Support Care Cancer Date: 2015-12-28 Impact factor: 3.603
Authors: Betty R Ferrell; Jennifer S Temel; Sarah Temin; Erin R Alesi; Tracy A Balboni; Ethan M Basch; Janice I Firn; Judith A Paice; Jeffrey M Peppercorn; Tanyanika Phillips; Ellen L Stovall; Camilla Zimmermann; Thomas J Smith Journal: J Clin Oncol Date: 2016-10-28 Impact factor: 44.544
Authors: Stein Kaasa; Jon H Loge; Matti Aapro; Tit Albreht; Rebecca Anderson; Eduardo Bruera; Cinzia Brunelli; Augusto Caraceni; Andrés Cervantes; David C Currow; Luc Deliens; Marie Fallon; Xavier Gómez-Batiste; Kjersti S Grotmol; Breffni Hannon; Dagny F Haugen; Irene J Higginson; Marianne J Hjermstad; David Hui; Karin Jordan; Geana P Kurita; Philip J Larkin; Guido Miccinesi; Friedemann Nauck; Rade Pribakovic; Gary Rodin; Per Sjøgren; Patrick Stone; Camilla Zimmermann; Tonje Lundeby Journal: Lancet Oncol Date: 2018-10-18 Impact factor: 41.316
Authors: Nanna B Finnerup; Simon Haroutounian; Peter Kamerman; Ralf Baron; David L H Bennett; Didier Bouhassira; Giorgio Cruccu; Roy Freeman; Per Hansson; Turo Nurmikko; Srinivasa N Raja; Andrew S C Rice; Jordi Serra; Blair H Smith; Rolf-Detlef Treede; Troels S Jensen Journal: Pain Date: 2016-08 Impact factor: 7.926